Current Options for the Pharmacotherapy of Obesity.

Abstract:

:650 millions of adults are obese worldwide - in the US alone, forty percent of the adults are obese. Although the obesity pandemic is constantly expanding at very high costs for health care systems, the currently available options of pharmacotherapy for obesity are rather limited. Despite intensive research efforts, the vast majority of the anti-obesity drugs developed up to now have a rather limited efficacy and/or safety profile. In the last fifty years, various drugs reached advanced states of clinical development but were either never marketed or were initially approved but withdrawn later due to safety issues. However, the understanding of the pathophysiology of obesity has been steadily improving and new, promising drugs targeting various selective obesityassociated and energy-homeostasis-related pathways are now available. When lifestyle changes alone fail to combat, then additional pharmacotherapy with an acceptable efficacy and safety profile could provide a useful therapeutic option.

journal_name

Curr Pharm Des

authors

Gouni-Berthold I,Berthold HK

doi

10.2174/1381612825666190708192630

subject

Has Abstract

pub_date

2019-01-01 00:00:00

pages

2019-2032

issue

18

eissn

1381-6128

issn

1873-4286

pii

CPD-EPUB-99478

journal_volume

25

pub_type

杂志文章,评审
  • Reactivity of Diterpenoid Quinones: Royleanones.

    abstract::Naturally occurring abietane diterpenoids have been studied over the years and have shown to display a wide range of biological activities. This review covers three main aspects of the abietane-type diterpenoids with hydroxy-p-quinone C ring, designated as royleanones. An overview of 1) the naturally occurrence, 2) ch...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612822666151211094521

    authors: Ladeiras D,Monteiro CM,Pereira F,Reis CP,Afonso CA,Rijo P

    更新日期:2016-01-01 00:00:00

  • Safety and efficacy of ximelagatran: meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism.

    abstract:BACKGROUND:Ximelagatran has been approved in Europe for VTE prophylaxis in orthopedic surgery at fixed doses and without laboratory monitoring. Aim of the study was to evaluate safety and efficacy of ximelagatran in a meta-analysis of prophylaxis and/or treatment randomized controlled trials. METHODS:Absolute risk of ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,meta分析

    doi:10.2174/138161205774580534

    authors: Iorio A,Guercini F,Ferrante F,Nenci GG

    更新日期:2005-01-01 00:00:00

  • Role of C reactive protein (CRP) in leptin resistance.

    abstract::Increased plasma levels of both leptin and C reactive protein (CRP) have been reported in a number of conditions, including obesity, and have been linked to cardiovascular pathophysiological processes and increased cardiovascular risk; interestingly these two biomarkers appear to be able to reciprocally regulate their...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/13816128113199990016

    authors: Hribal ML,Fiorentino TV,Sesti G

    更新日期:2014-01-01 00:00:00

  • Towards histone deacetylase inhibitors as new antimalarial drugs.

    abstract::Histone deacetylases (HDACs) are important enzymes that effect post-translational modifications of proteins by altering the acetylation state of lysine residues. HDACs control epigenetic changes that trigger cell transformation and proliferation of transformed cells associated with many diseases. These enzymes are val...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:

    authors: Andrews KT,Tran TN,Fairlie DP

    更新日期:2012-01-01 00:00:00

  • Gender differences in the clinical presentation of heart disease.

    abstract::The clinical presentation of heart disease is different between men and women and this distinction is pivotal for a correct diagnosis and an adequate treatment. However, the definition of symptoms classically associated with heart disease is mainly based on the characteristics of those reported in men. Chest pain or c...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/138161211795656927

    authors: Collins P,Vitale C,Spoletini I,Barbaro G

    更新日期:2011-01-01 00:00:00

  • Barriers to Risk Stratification Accuracy in Ischemic Heart Disease in Women: The Role of Non-Obstructive Coronary Artery Disease.

    abstract:BACKGROUND:A substantial part of literature has been centered on sex differences in the clinical aspects of ischemic heart disease (IHD). Many reports have documented differences in the presentation and risk profile between women and men. Such differences drive sex-related inequalities in the referral and treatment of ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612822666160311115344

    authors: Cenko E,Bugiardini R

    更新日期:2016-01-01 00:00:00

  • Ion Channel and Neurotransmitter Modulators as Electroceutical Approaches to the Control of Cancer.

    abstract::The activities of individual cells must be tightly coordinated in order to build and maintain complex 3- dimensional body structures during embryogenesis and regeneration. Thus, one way to view cancer is within systems biology as a network disorder affecting the ability of cells to properly interact with a morphodynam...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612823666170530105837

    authors: Tuszynski J,Tilli TM,Levin M

    更新日期:2017-01-01 00:00:00

  • Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.

    abstract::Agomelatine markedly differs from other classes of antidepressant drugs: its primary molecular targets in vivo are the melatonin MT(1) and MT(2) receptors, where it acts as a potent agonist, and the 5-HT(2C) receptors, where it exerts clear-cut antagonist properties. Agomelatine across a wide range of clinical trials ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161209788168056

    authors: Bourin M,Prica C

    更新日期:2009-01-01 00:00:00

  • Blood serum atherogenicity and coronary artery calcification.

    abstract::The phenomenon of blood serum atherogenicity was described as the ability of human serum to induce lipid accumulation in cultured cells. The results of recent two-year prospective study in asymptomatic men provided the evidence for association between the changes in serum atherogenicity and dynamics of carotid intima-...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612820666140212194614

    authors: Sobenin IA,Myasoedova VA,Anisimova EV,Pavlova XN,Möhlenkamp S,Schmermund A,Seibel R,Berenbein S,Lehmann N,Moebus S,Jöckel K,Orekhov AN,Erbel R

    更新日期:2014-01-01 00:00:00

  • Perioperative Management of DOACs in Vascular Surgery: A Practical Approach.

    abstract:BACKGROUND:Approximately 10-15% of patients on DOACs have to interrupt their anticoagulant before an invasive procedure every year. The perioperative management and monitoring of DOACs have proved to be challenging, as differences in patients' status and in the invasiveness of each procedure develop different situation...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612825666181226154746

    authors: Kouvelos G,Matsagkas M,Rousas N,Nana P,Mpatzalexis K,Stamoulis K,Giannoukas A,Arnaoutoglou E

    更新日期:2018-01-01 00:00:00

  • Perinatal gene transfer to the liver.

    abstract::The liver acts as a host to many functions hence raising the possibility that any one may be compromised by a single gene defect. Inherited or de novo mutations in these genes may result in relatively mild diseases or be so devastating that death within the first weeks or months of life is inevitable. Some diseases ca...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161211797247541

    authors: McKay TR,Rahim AA,Buckley SM,Ward NJ,Chan JK,Howe SJ,Waddington SN

    更新日期:2011-01-01 00:00:00

  • Hypertension - Current Natural Strategies to Lower Blood Pressure.

    abstract::The prevalence of hypertension (HTN) worldwide is high and is constantly rising. HTN is considered to be a silent killer since often there are no obvious symptoms but long-term, HTN significantly increases the risk of coronary heart disease and cerebrovascular diseases. Those with diagnosed HTN or at high risk of its ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612823666170215144649

    authors: Rysz J,Franczyk B,Banach M,Gluba-Brzozka A

    更新日期:2017-01-01 00:00:00

  • Detecting Personalized Determinants During Drug Treatment from Omics Big Data.

    abstract:BACKGROUNDS:Targeted therapy is the foundation of personalized medicine in cancer, which is often understood as the right patient using the right drug. Thinking from the viewpoint of determinants during personalized drug treatment, the genetics, epigenetics and metagenomics would provide individual-specific biological ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612824666181106102111

    authors: Wang L,Yu X,Zhang C,Zeng T

    更新日期:2018-01-01 00:00:00

  • Peptide antagonist of the androgen receptor.

    abstract::Androgen receptor (AR) is a steroid hormone receptor that is activated by endogenous androgens, mainly testosterone and 5alpha-dihydrotestosterone (5alpha-DHT). AR is also an important drug target, and AR antagonists (antiandrogens) have been widely used for prostate cancer therapy. Antiandrogens currently available o...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161210790963850

    authors: Gao W

    更新日期:2010-01-01 00:00:00

  • Recent Advances in Nutrition for the Treatment of Depressive Disorder.

    abstract::Depression is one of the leading causes of disability in the world. Current pharmaceutical treatment for depression remains unsatisfactory due to its limited therapeutic efficacy and undesirable side effects. There is increasing interest in looking for alternative strategies from diet for the treatment of depressive d...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612824666180803113106

    authors: Wang X,Zhao F,Wang X,Niu Y,Niu L,Wang C

    更新日期:2018-01-01 00:00:00

  • Adenosine and ischemic preconditioning.

    abstract::Adenosine is released in large amounts during myocardial ischemia and is capable of exerting potent cardioprotective effects in the heart. Although these observations on adenosine have been known for a long time, how adenosine acts to achieve its anti-ischemic effect remains incompletely understood. However, recent ad...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:

    authors: Liang BT,Jacobson KA

    更新日期:1999-12-01 00:00:00

  • Identification of the descriptor pharmacophores using variable selection QSAR: applications to database mining.

    abstract::The pharmacophore concept is central to the rational drug design and discovery process. Traditionally, a pharmacophore is defined as a specific three-dimensional (3D) arrangement of chemical functional groups found in active molecules, which are characteristic of a certain pharmacological class of compounds. Herein, b...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612013397834

    authors: Tropsha A,Zheng W

    更新日期:2001-05-01 00:00:00

  • Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction.

    abstract::Erectile dysfunction (ED) has multifactor pathogenesis, with neurological, vascular, endocrinological and psychogenic components described. However, about 50-85% of ED population report the presence of one or more comorbidities i.e. hypertension, diabetes, cardiovascular disease, dyslipidemia which all impair endothel...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161206778343046

    authors: Aversa A,Bruzziches R,Pili M,Spera G

    更新日期:2006-01-01 00:00:00

  • Developing antiangiogenic peptide drugs for angiogenesis-related diseases.

    abstract::Angiogenesis is regulated by stimulators and inhibitors and involve multiple biological processes including endothelial cell proliferation, migration, cell-cell and cell-matrix adhesion, assembly into tube structures as well as apoptosis. Designing and developing peptides for therapeutic application to inhibit angioge...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/138161207781039715

    authors: Sulochana KN,Ge R

    更新日期:2007-01-01 00:00:00

  • Topical delivery of drugs for the effective treatment of fungal infections of skin.

    abstract::The prevalence of fungal infections of skin has increased rapidly, affecting approximately 40 million people across the globe. A wide variety of antifungal drugs has been utilized in the effective management of numerous dermatological infections. Topical treatment of fungal infections has proved to be quite advantageo...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612821666150428150456

    authors: Akhtar N,Verma A,Pathak K

    更新日期:2015-01-01 00:00:00

  • Deregulated bone morphogenetic protein receptor signaling underlies fibrodysplasia ossificans progressiva.

    abstract::Transforming growth factor-β family members, which include TGF-βs, activins and bone morphogenetic proteins (BMPs), play important roles in development and maintaining tissue homeostasis. The extracellular TGF-β family members signal across the plasmamembrane by activating type I and type II serine/threonine kinase re...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/138161212802430495

    authors: de Gorter DJ,Jankipersadsing V,Ten Dijke P

    更新日期:2012-01-01 00:00:00

  • Renin-angiotensin antagonists: therapeutic effects beyond blood pressure control?

    abstract::Guidelines for the treatment of hypertension allow a wide range of choices to the physicians; however some differences are present about the preferred drugs to start treatment. The most important aim remains an adequate decrease of blood pressure, something not perfectly obtained in the general population, but some cl...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161212799436575

    authors: Pende A,Dallegri F

    更新日期:2012-01-01 00:00:00

  • Receptor binding ligands to image infection.

    abstract::The current gold standard for imaging infection is radiolabeled white blood cells. For reasons of safety, simplicity and cost, it would be desirable to have a receptor-specific ligand that could be used for imaging infection and that would allow a differential diagnosis between sterile and septic inflammatory processe...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161208786549416

    authors: Chianelli M,Boerman OC,Malviya G,Galli F,Oyen WJ,Signore A

    更新日期:2008-01-01 00:00:00

  • Nanoparticle-Based Combination Therapy for Cancer Treatment.

    abstract::In recent years, combination of different types of therapies using nanoparticles has emerged as an advanced strategy for cancer treatment. Most of all, combination of chemotherapeutic drug and siRNA in nanoformulation has shown a great potential, because siRNA-mediated specific gene silencing can compensate for the in...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612821666150531165059

    authors: Yhee JY,Son S,Lee H,Kim K

    更新日期:2015-01-01 00:00:00

  • Expression of P-gp in Glioblastoma: What we can Learn from Brain Development.

    abstract::P-Glycoprotein (P-gp) is a 170-kDa transmembrane glycoprotein that works as an efflux pump and confers multidrug resistance (MDR) in normal tissues and tumors, including nervous tissues and brain tumors. In the developing telencephalon, the endothelial expression of P-gp, and the subcellular localization of the transp...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/1381612826666200318130625

    authors: de Trizio I,Errede M,d'Amati A,Girolamo F,Virgintino D

    更新日期:2020-01-01 00:00:00

  • Vitamins in Heart Failure: Friend or Enemy?

    abstract:BACKGROUND:The failing heart is characterized by a depleted metabolic energy reserve and the upregulation of several molecular mechanisms leading to cardiac hypertrophy, inflammation, fibrosis, angiogenesis, and apoptosis. Dietary or non-dietary supplementation of vitamins could potentially benefit energy balance. OBJ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612823666170321094711

    authors: Georgiopoulos G,Chrysohoou C,Vogiatzi G,Magkas N,Bournelis I,Bampali S,Gruson D,Tousoulis D

    更新日期:2017-01-01 00:00:00

  • Inflammatory mediators in epilepsy.

    abstract::All common contributing factors to epilepsy such as trauma, malignancies and infections are accompanied by different levels of central nervous system inflammation that in turn have been associated with the occurrence of seizure. Emerging data from human brain tissue and experimental models of epilepsy support the prop...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612811319380009

    authors: Lorigados Pedre L,Morales Chacón LM,Orozco Suárez S,Pavón Fuentes N,Estupiñán Díaz B,Serrano Sánchez T,García Maeso I,Rocha Arrieta L

    更新日期:2013-01-01 00:00:00

  • Angiotensin II type 1 and type 2 receptor-induced cell signaling.

    abstract::The octapeptide angiotensin II (Ang II) plays a homeostatic role in the regulation of blood pressure and water and electrolyte balance, and also contributes to the progression of cardiovascular remodeling. Ang II activates Ang II type 1 (AT1) receptor and type 2 (AT2) receptor, both of which belong to the seven-transm...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612811319170003

    authors: Akazawa H,Yano M,Yabumoto C,Kudo-Sakamoto Y,Komuro I

    更新日期:2013-01-01 00:00:00

  • Locked nucleic acid holds promise in the treatment of cancer.

    abstract::Providing novel treatments to help cancer patients live longer and have better lives remains one of the biggest challenges of the pharmaceutical industry. Today much is known about the molecular and genetic causes of cancers thus facilitating the development of novel targeted cancer drugs with improved risk-benefit ra...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161208784246234

    authors: Frieden M,Ørum H

    更新日期:2008-01-01 00:00:00

  • Nanoparticulated Polymeric Systems for Gene Delivery.

    abstract::Gene therapy, currently, represents one of the new therapies that have emerged for the treatment of different diseases. Between the different approaches that can be chosen concerning this therapy, gene delivery with non-viral systems has focused the attention during the past decades, because of the reduced toxicity co...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612821666150901100037

    authors: Urbiola K,Blanco-Fernandez L,de Ilarduya CT

    更新日期:2015-01-01 00:00:00